Analogs of fibroblast growth factor 19/21 (FGF 19/21) are also currently undergoing phase II clinical trials to evaluate utility in improving fibrosis in NASH patients [159,160]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.